Fri 11/16/2018 00:13 ET
DJIA25289.27209.900.83%TELCO167.960.790.47%GOLD1216.201.220.10%Shanghai2687.0419.080.71%
S&P 5002730.2028.941.06%BANKS448.538.791.96%OIL56.910.450.79%BITCOIN5604.3942.590.76%
NASDAQ7259.03124.861.72%PHARM580.584.240.73%US/EU1.130.000.00%Futures2731.503.000.11%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Daxor Corp - DXR   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add DXR
  
From: SunTzu772 (Rep: 1078) reply to SunTzu772Date: 11/08/2018 13:59
Forum: Daxor Corp - Msg #109Thread #674044798 (Rec: 0)
New Data Demonstrating the Clinical Utility of Daxor’s BVA-100 in Hypertension Management to be Presented at the American Heart Association’s Scientific Sessions 2018

----

Daxor to Exhibit at American Heart Association 2018

----
NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be attending the American Heart Association Scientific Sessions (AHA) at the McCormick Place Convention Center in Chicago, IL from November 10-12th, 2018. A presentation by Marat Fudim, M.D. of Duke University Medical Center demonstrating the clinical utility of blood volume analysis to help guide hypertension management will be featured.
“The AHA Annual Meeting is a leading event gathering over 12,000 experts from around the world focused on reducing disabilities and death from cardiovascular disease and stroke. Eighty-five percent of heart failure patients have a known history of hypertension. We are looking forward to sharing with leaders in the field how our BVA-100 (Blood Volume Analyzer) has been proven to not only reduce heart failure 30-day mortality by 82% and 30-day readmissions by 56%, but also how volume management is an essential component to help guide hypertension therapy. The Centers for Disease Control and Prevention estimates one in three adults have hypertension (or high blood pressure), a leading cause of stroke, heart attack and kidney failure,” said Michael Feldschuh, CEO of Daxor Corporation. The company will be exhibiting at Booth #2016.

----

https://globenewswire.com/news-release/2018/11/08/1648405/0/en/New-Data-Demonstrating-the-Clinical-Utility-of-Daxor-s-BVA-100-in-Hypertension-Management-to-be-Presented-at-the-American-Heart-Association-s-Scientific-Sessions-2018.html



------------------- "Opportunities multiply as they are seized" -- Sun Tzu circa 500 B.C. -------------------



Reply to SunTzu772 - Msg #107 - 11/07/2018 10:30

7.49 US Army contract...difficult to get any bigger.

----

Daxor Corporation Selected for U.S. Army Contract to Develop a Blood Volume Analyzer for Improvement of Combat Casualty Care

----

November 07, 2018 08:30 ET | Source: Daxor Corporation
----

NEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the U.S. Army has selected it for a contract award to develop a blood volume analyzer for improving combat casualty care.
----
The selection was made under the Defense Department’s Small Business Innovative Research (SBIR) program. The contract award will be to develop and demonstrate a prototype blood volume analyzer suitable for military use leveraging Daxor’s technology and experience with blood volume measurement devices. “Hemorrhage is the primary cause of death in about 30% of injured soldiers,” said Michael Feldschuh, CEO of Daxor Corporation. “Direct blood volume measurement has been shown to improve outcomes in a broad range of acute and chronic medical conditions. Our existing technology platform and patent portfolio is an ideal foundation for developing a rapid, rugged, portable blood volume analyzer that can improve prehospital resuscitation on the battlefield, potentially saving many lives.”

----
"This is an exciting additional opportunity to push our research and development program forward,” says Jonathan Feldschuh, Chief Scientific Officer. “We are focused on making volume measurement easier and quicker to perform, whether in a hospital lab, on the battlefield, or at the patient bedside.”
This is a first-time award for Daxor. SBIR contracts are designed to stimulate innovation by companies to develop technologies and solutions that meet critical Army needs. SBIR programs benefit the Department of Defense (DoD) and the private sector and support the nation’s economic growth.
----

About Daxor Corporation
Daxor Corporation is an innovative medical instrumentation and biotechnology company. We manufacture the BVA-100 Blood Volume Analyzer, the first instrument approved by the FDA to provide rapid direct measurement of a patient’s blood volume. We believe that the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions. It is our goal, working in conjunction with hospitals and clinics, to achieve that possibility. Ultimately the company’s mission is to help hospitals and physicians incorporate Daxor’s BVA-100 diagnostic to significantly improve the quality of patient care. For more information please visit our website at http://www.daxor.com.
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser SunTzu772: Reward | Watch | IgnoreDXR: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add DXR
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.